Antihypertensive treatment, new cases of diabetes and other controversies;Tratamiento antihipertensivo, nuevos casos de diabetes y otras controversias

Revista Medica de Rosario

Volumn 74, Issue 3, 2008, Pages 135-147

  Zamora, Sebastián García ^a,b   Parodi, Roberto L ^c,d   Gallo, Roberto ^c,d   Nannini, Diego ^d   Filippini, Fernando ^c,e   Piskorz, Daniel ^d,e,f   Greca, Alcides A ^c,d,g  

^a Cátedra de Clínica Médica   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d Asociación de Hipertensión Arterial de Rosario   (Argentina)

^e UNR ^*  (Argentina)

^f SOCIEDAD ARGENTINA DE CARDIOLOGÍA   (Argentina)

^g Hospital Centenario de Rosario   (Argentina)

Author keywords

Diabetes; Hypertension; Side effects; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; HUMAN; HYPERTENSION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW;

EID: 61449089580     PISSN: 03275019     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 370: 591-603, 2007.
2. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet 366: 1510-2, 2005.
3. Doval HC, Tajer CD. Evidencias en Cardiología IV. De los ensayos clínicos a las conductas terapeúticas. Ed. CEDIC, Buenos Aires 2005.
4. The Seventh Report of the Join National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560-72, 2003.
5. Vasan RS, Larson MG, Leip EP, y col. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291-7, 2001.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967-75, 2000.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-97, 2002.
8. Stevo J. The ALLHAT study: if you believe in evidence-based medicine, stick to it! J Hypertens 21: 453-4, 2003.
9. Meltzer JI. A clinical specialist in hypertension critiques JNC 7. Am J Hypertens 18: 894-8, 2005.
10. Wing LM, Reid CM, Ryan P, et al., for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-92, 2003.
11. Appel LJ. The verdict from ALLHAT- Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288: 3039-42, 2002.
12. Psaty BM, Lumley T, Furberg CD, y col. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289: 2534-44, 2003.
13. Austin PC, Mamdani MM, Tu K, Zwarenstein M. Changes in prescribing patterns following publication of the ALLHAT trial. JAMA 291: 44-5, 2004.
14. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201-7, 2007.
15. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30: 487-96, 2004.
16. Andraws R, Brown DL Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiology 99: 1006-12, 2007.
17. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24: 3-10, 2006.
18. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46: 821-6, 2005
19. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiology 100: 1254-62, 2007.
20. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiol Drug Safety 16: 979-87, 2007.
21. Lam SKH, Owen A. Incident diabetes in clinical trials of antihypertensive drugs (Letter). Lancet 369: 1513-4, 2007.
22. Johnston GD. Incident diabetes in clinical trials of antihypertensive drugs (Letter). Lancet 369: 1514, 2007.
23. Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. J Hypertens 24(1 Suppl):S57-63, 2006.
24. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30: 498-505, 2004.
25. Carter BL, Basile J. Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens 7: 638-40, 2005.
26. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 42: S17-S25, 2005.
27. Messerlia FH, Grossman E, Leonettic G. Antihypertensive therapy and new onset diabetes. J Hypertens 22: 1845-7, 2004.
28. Nilsson PM, Cifkova R, Kjeldsen SE, Mancia G. Update on hypertension management: Prevention of type 2 diabetes mellitus with antihypertensive drugs. Eur Soc Hypertens Scient Newsl 12: 2478-82, 2006.
29. Verdecchia P, Reboldi G, Angeli F, y col. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43: 963-9, 2004
30. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 25: 1311-7, 2007.
31. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br Med J 326: 681, 2003.
32. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29-35, 2005.
33. McMurray JJV. ACE inhibitors in cardiovascular disease - Unbeatable? (Editorial). N Engl J Med 358: 1615-16, 2005.
34. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-59, 2008.
35. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens 23: 1113-20, 2005.
36. Williams B. Evolution of hypertensive disease: a revolution in guidelines. Lancet 368: 6-8, 2006.
37. Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 368: 555-6, 2006.
38. Staessen JA, Birkenhäger WH. Evidence that new antihypertensives are superior to older drugs. Lancet 366: 869-71, 2005.